NEW YORK--(BUSINESS WIRE)--Establishment Labs Holdings Inc. (NASDAQ: ESTA), a global medical technology company dedicated to improving women’s health and wellness, principally in breast aesthetics and reconstruction, today announced that it has surpassed more than five million Motiva devices in market. This milestone underscores the company’s long‑standing commitment to science‑based innovation and reflects sustained global adoption of Motiva’s portfolio of breast aesthetics and reconstruction s

LAS VEGAS, April 7, 2026 /PRNewswire/ -- Avaí Bio, Inc. (OTCQB: AVAI) ("Avaí" or the "Company"), an emerging biotechnology company developing transformative cell-based therapies for diabetes, age-related disorders, and anti-aging, today announced that in collaboration with its joint venture partner, Austrianova, a global biotechnology company, it will present the latest data from its α-Klotho anti-aging therapy. The presentation will take place at the Second Annual Klotho Conference, which focus

New solution provides a single AI-enabled centralized clinical data repository to enable reusable risk adjustment, quality performance, audit response, and care management documentation LOS ANGELES, April 7, 2026 /PRNewswire/ -- Reveleer, a leading provider of AI-enabled solutions empowering data-driven health plan performance, today announced the launch of Clinical Data Repository, a centralized, AI-enabled clinical data management solution designed to help health plans reliably store and reus

Building on the Program's Success, Koch has Expanded its Partnership with Pomelo to Include Doula Support and Midlife Care NEW YORK, April 7, 2026 /PRNewswire/ -- Today, Pomelo Care, the national leader in evidence-based healthcare for women and children, released a case study highlighting the impact of its partnership with Koch, one of the largest private companies in the United States. This analysis demonstrates that the program meaningfully improved maternal and infant outcomes. The case stud

Volta Medical's artificial intelligence (AI) enhanced mapping and clinical evidence to be showcased across multiple scientific sessions MARSEILLE, France, April 7, 2026 /PRNewswire/ -- Volta Medical, committed to revolutionizing care for underserved complex atrial fibrillation (AF) patients with breakthrough AI solutions, today announced a full slate of presentations featuring its technology at the Heart Rhythm Society (HRS) 2026 Annual Meeting, taking place April 23–26 in Chicago, IL. Volta Med

New 9amHealth Report Finds GLP-1s Are Now a Top 3 Benefit—While Cost Remains the #1 Barrier SAN DIEGO, April 7, 2026 /PRNewswire/ -- GLP-1 medications have officially crossed from trending to expected in the workplace, according to 9amHealth's new consumer survey. The share of respondents using GLP-1s has more than doubled since 2023, reaching 49%. This number signals a fundamental shift in employee expectations—and creates new challenges for employers trying to balance access with cost. GLP-1

New research reveals 80% of clinicians trust evidence-based AI tools, while 54% of consumers say trust decreases with general-purpose AI usage, highlighting evidence as the critical bridge to patient confidence. IPSWICH, Mass., April 7, 2026 /PRNewswire/ -- EBSCO Clinical Decisions today announced the release of its latest research report, "The Clinician-Patient Trust Dynamic in the Era of AI-Powered Clinical Decision Support (AI-CDS)." Drawing on surveys of 1,000 U.S. clinicians and 1,000 U.S.

HACKENSACK, N.J., April 7, 2026 /PRNewswire/ -- Royal Biologics, a leader in regenerative medicine and advanced wound care technologies, today announced that Fibrinet® PRF Wound Matrix has received U.S. Food and Drug Administration (FDA) clearance for the management of exuding cutaneous wounds, including diabetic and venous ulcers. Fibrinet® PRF Wound Matrix is a point-of-care system designed to harness and concentrate a patient's own platelets and associated growth factors into a durable Platel

TAMPA, Fla.--(BUSINESS WIRE)--PaceMate, a tech-enabled cardiac device monitoring platform managing care for more than 2.3 million patients at health systems nationwide, announced the appointment of Dr. Benjamin A. Steinberg as Chief Medical Officer. A nationally recognized leader in cardiac electrophysiology, NIH-funded researcher, and author of nearly 200 peer-reviewed publications, Dr. Steinberg brings to PaceMate a rare combination of clinical depth, research rigor, and real-world expertise i

DALLAS--(BUSINESS WIRE)--As demand for GLP-1 medications continues to surge across the U.S., accelerated by expanding clinical indications, more market entrants, and novel pricing and access models, new research suggests employer-sponsored health benefits may play a significant role in determining who ultimately uses these treatments. A national survey conducted by The Harris Poll on behalf of Wondr Health, the leading provider of behavioral weight management and GLP-1 clinical solutions, finds